^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for Treatment of Acute Myeloid Leukemia, Including Wild-Type and FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Disease

Published date:
11/06/2019
Excerpt:
In vivo studies using a MOLM-13 systemic model of FLT3-ITD AML demonstrated that LAM-003 monotherapy significantly improved animal survival and that the combination of LAM-003 and venetoclax significantly prolonged animal survival compared with each single agent.
DOI:
https://doi.org/10.1182/blood-2019-125770